Bermekimab
- Generic Name
- Bermekimab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1401965-15-8
- Unique Ingredient Identifier
- N6SVN735GY
- Background
Bermekimab is under investigation in clinical trial NCT01384630 (Safety, Pharmacokinetics, and Efficacy of RA-18C3 in Subjects With Moderate to Severe Psoriasis).
- Associated Conditions
- -
- Associated Therapies
- -
A Study of Bermekimab for the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis
- First Posted Date
- 2021-08-04
- Last Posted Date
- 2023-05-24
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 6
- Registration Number
- NCT04990440
- Locations
- ๐ฆ๐ท
Conexa Investigacion Clinica S.A., Caba, Argentina
๐ฆ๐ทClรญnica Adventista Belgrano, Caba, Argentina
๐ฆ๐ทCINME - Centro de Investigaciones Metabolicas, Ciudad de Buenos Aires, Argentina
A Study of Bermekimab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa
- Conditions
- Interventions
- First Posted Date
- 2021-08-03
- Last Posted Date
- 2023-11-13
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 151
- Registration Number
- NCT04988308
- Locations
- ๐บ๐ธ
Medical Dermatology Specialists, Phoenix, Arizona, United States
๐บ๐ธForcare Clinical Research, Inc., Tampa, Florida, United States
๐บ๐ธAllcutis Research, Beverly, Massachusetts, United States
A Study of Bermekimab (JNJ-77474462) in the Treatment of Participants With Moderate to Severe Atopic Dermatitis
- Conditions
- Interventions
- First Posted Date
- 2021-03-10
- Last Posted Date
- 2023-03-01
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 199
- Registration Number
- NCT04791319
- Locations
- ๐บ๐ธ
Park Avenue Dermatology, Orange Park, Florida, United States
๐บ๐ธClinical Partners, Johnston, Rhode Island, United States
๐จ๐ฆCentre De Recherche Dermatologique Du Quebec Metropolitan, Quebec, Canada
A Study to Evaluate the Efficacy, Safety and Tolerability of Bermekimab in Patients With Hidradenitis Suppurativa
- Conditions
- Interventions
- First Posted Date
- 2019-07-15
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 153
- Registration Number
- NCT04019041
- Locations
- ๐บ๐ธ
University of Southern California, Los Angeles, California, United States
๐บ๐ธP&S Research, LLC, Miami, Florida, United States
๐บ๐ธDawes Fretzin Clinical Research Group, Indianapolis, Indiana, United States
Phase II Trial of RA-18C3 in Subjects With Moderate to Severe Acne Vulgaris
- First Posted Date
- 2011-11-18
- Last Posted Date
- 2021-02-17
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 11
- Registration Number
- NCT01474798
- Locations
- ๐บ๐ธ
Meridien Research, Saint Petersburg, Florida, United States
๐บ๐ธMoy, Fincher, and Chipps Facial Plastics and Dermatology, Beverly Hills, California, United States
๐บ๐ธAustin Dermatology Associates, Austin, Texas, United States
Safety, Pharmacokinetics, and Efficacy of RA-18C3 in Subjects With Moderate to Severe Psoriasis
- First Posted Date
- 2011-06-29
- Last Posted Date
- 2021-02-17
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 8
- Registration Number
- NCT01384630
- Locations
- ๐บ๐ธ
West Kentucky Dermatology, Owensboro, Kentucky, United States
๐บ๐ธWestlake Dermatology, Austin, Texas, United States
๐บ๐ธUniversity of Michigan, Ann Arbor, Michigan, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.